Genus Valuation

Is GNS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GNS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: GNS (£19.2) is trading below our estimate of fair value (£19.82)

Significantly Below Fair Value: GNS is trading below fair value, but not by a significant amount.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for GNS?

Other financial metrics that can be useful for relative valuation.

GNS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.2x
Enterprise Value/EBITDA19.2x
PEG Ratio4x

Price to Sales Ratio vs Peers

How does GNS's PS Ratio compare to its peers?

The above table shows the PS ratio for GNS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average8x
OXB Oxford Biomedica
4x19.9%UK£358.2m
BVXP Bioventix
14.8x7.2%UK£201.0m
AVCT Avacta Group
11.6x11.1%UK£269.1m
TRX Tissue Regenix Group
1.8x15.3%UK£43.5m
GNS Genus
1.9x4.1%UK£1.3b

Price-To-Sales vs Peers: GNS is good value based on its Price-To-Sales Ratio (1.9x) compared to the peer average (8x).


Price to Earnings Ratio vs Industry

How does GNS's PE Ratio compare vs other companies in the GB Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a35.1%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a35.1%
n/an/an/a
No more companies

Price-To-Sales vs Industry: GNS is good value based on its Price-To-Sales Ratio (1.9x) compared to the European Biotechs industry average (8.7x).


Price to Sales Ratio vs Fair Ratio

What is GNS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GNS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.9x
Fair PS Ratio4.6x

Price-To-Sales vs Fair Ratio: GNS is good value based on its Price-To-Sales Ratio (1.9x) compared to the estimated Fair Price-To-Sales Ratio (4.6x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GNS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUK£19.20
UK£26.16
+36.2%
13.4%UK£31.00UK£21.50n/a6
Sep ’25UK£17.84
UK£26.66
+49.4%
12.1%UK£31.00UK£21.50n/a6
Aug ’25UK£18.24
UK£26.50
+45.3%
12.7%UK£31.00UK£21.50n/a6
Jul ’25UK£16.56
UK£27.78
+67.8%
15.9%UK£35.00UK£23.00n/a6
Jun ’25UK£18.02
UK£27.78
+54.2%
15.9%UK£35.00UK£23.00n/a6
May ’25UK£17.36
UK£27.78
+60.0%
15.9%UK£35.00UK£23.00n/a6
Apr ’25UK£17.65
UK£29.62
+67.8%
14.7%UK£35.00UK£23.09n/a6
Mar ’25UK£17.40
UK£29.62
+70.2%
14.7%UK£35.00UK£23.09n/a6
Feb ’25UK£22.24
UK£33.09
+48.8%
20.9%UK£45.00UK£23.17n/a6
Jan ’25UK£21.70
UK£33.09
+52.5%
20.9%UK£45.00UK£23.17n/a6
Dec ’24UK£19.09
UK£33.09
+73.3%
20.9%UK£45.00UK£23.17n/a6
Nov ’24UK£21.82
UK£34.10
+56.3%
16.7%UK£45.00UK£27.80n/a6
Oct ’24UK£20.96
UK£34.10
+62.7%
18.1%UK£45.00UK£25.80n/a6
Sep ’24UK£23.00
UK£35.59
+54.7%
14.9%UK£45.00UK£30.42UK£17.846
Aug ’24UK£24.40
UK£38.82
+59.1%
17.9%UK£50.00UK£30.42UK£18.246
Jul ’24UK£21.66
UK£38.82
+79.2%
17.9%UK£50.00UK£30.42UK£16.566
Jun ’24UK£25.18
UK£38.82
+54.2%
17.9%UK£50.00UK£30.42UK£18.026
May ’24UK£26.88
UK£42.36
+57.6%
21.2%UK£60.00UK£32.00UK£17.366
Apr ’24UK£28.74
UK£42.36
+47.4%
21.2%UK£60.00UK£32.00UK£17.656
Mar ’24UK£29.98
UK£43.80
+46.1%
20.9%UK£60.00UK£32.00UK£17.405
Feb ’24UK£28.50
UK£42.95
+50.7%
17.3%UK£57.00UK£32.00UK£22.246
Jan ’24UK£29.84
UK£42.95
+43.9%
17.3%UK£57.00UK£32.00UK£21.706
Dec ’23UK£29.70
UK£43.14
+45.3%
18.9%UK£57.00UK£32.00UK£19.095
Nov ’23UK£26.18
UK£44.73
+70.9%
18.2%UK£55.00UK£32.00UK£21.826
Oct ’23UK£26.18
UK£44.73
+70.9%
18.2%UK£55.00UK£32.00UK£20.966
Sep ’23UK£23.74
UK£46.35
+95.2%
17.0%UK£57.80UK£35.00UK£23.006

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies